We report 3 cases of squamous cell carcinoma arising respectively after 30, 6 and 19 years of spontaneous evolution of cutaneous discoid lupus erythematosus. In each case the histopathologic examination confirmed the diagnosis of cutaneous lupus discoid and squamous cell carcinoma. As phagedenic ulcer which is the main preneoplastic dermatosis, discoid lupus erythematosis must be considered. The long duration before the cancerisation allows a correct treatment of the disease to prevent the transformation.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Identification of PIF1 as a Ferroptosis-Related Prognostic Biomarker Correlated with Immune Infiltration in Hepatocellular Carcinoma.
Appl Biochem Biotechnol
January 2025
Department of General Surgery, Shanxi Provincial Cancer Hospital/Shanxi Hospital Cancer Hospital of Chinese Academy of Medical Sciences, No. 3, Gongye New Street , Xinhualing District, Taiyuan, 030001, China.
Hepatocellular carcinoma (HCC) is a primary liver malignancy characterized by high morbidity and mortality. Recently, ferroptosis has been recognized as an important factor in regulating cell growth in HCC. However, the role of ferroptosis-related genes in HCC remains unclear.
View Article and Find Full Text PDFEbastine-mediated destabilization of E3 ligase MKRN1 protects against metabolic dysfunction-associated steatohepatitis.
Cell Mol Life Sci
January 2025
Department of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul, 03722, Republic of Korea.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a chronic condition encompassing metabolic dysfunction-associated steatotic liver (MASL) and metabolic dysfunction-associated steatohepatitis (MASH), which can progress to fibrosis, cirrhosis, or hepatocellular carcinoma (HCC). The heterogeneous and complex nature of MASLD complicates optimal drug development. Ebastine, an antihistamine, exhibits antitumor activity in various types of cancer.
View Article and Find Full Text PDFDevelopment and biological evaluation of a novel CEACAM6-targeted PET tracer for distinguishing malignant nodules in early-stage lung adenocarcinoma.
Eur J Nucl Med Mol Imaging
January 2025
School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
Purpose: Low-dose CT (LDCT) screening effectively reduces lung adenocarcinoma (LUAD) mortality. However, accurately evaluating the malignant potential of indeterminate lung nodules remains a challenge. Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6), a potential biomarker for distinguishing benign pulmonary nodules from LUAD, may be leveraged for noninvasive positron emission tomography (PET) imaging to aid LUAD diagnosis.
View Article and Find Full Text PDFPeriductal fibroblasts participate in liver homeostasis, fibrosis, and tumorigenesis.
J Exp Med
April 2025
Key Laboratory of Multi-Cell System, Shanghai Institute of Biochemistry and Cell Biology, CAS Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.
Hepatic fibroblasts comprise groups of stromal cells in the liver that are phenotypically distinct from hepatic stellate cells. However, their physiology is poorly understood. By single-cell RNA sequencing, we identified Cd34 and Dpt as hepatic fibroblast-specific genes.
View Article and Find Full Text PDFAssessing the Correlation Between Langerhans Cells Population and Prognosis of Tongue Squamous Cell Carcinoma.
Clin Exp Dent Res
February 2025
School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran.
Background And Objective: Tongue squamous cell carcinoma (TSCC) is the most prevalent oral cancer. Despite considerable advancements in treatment, the 5-year survival rate remains relatively unchanged. Langerhans cells (LCs) play an important role in antitumor immunity.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!